Diagnostics

News and analysis on diagnostic technologies and applications.

DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.

The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.

The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.

UgenTec and R-Biopharm's collaboration will cover the software's development, regulatory approval, and launch.

The company will use the net proceeds to finance its current operations and expand its US commercialization capacities for its lead product, Epi proColon.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.